Semi-Annual Report
August 31, 2023 (Unaudited)

Tema ETF Trust

Tema American Reshoring ETF

| RSHO

| NYSE Arca, Inc.

Tema Monopolies and Oligopolies ETF

| TOLL

| CBOE BZX Exchange, Inc.

Tema Luxury ETF

| LUX

| NYSE Arca, Inc.

Tema Oncology ETF

| CANC

| NASDAQ Stock Market LLC

Tema Global Royalties ETF

| ROYA

| CBOE BZX Exchange, Inc.

Tema ETF Trust

Table of Contents

 

Page

Portfolio Allocations by Sector and Country

1

Tema American Reshoring ETF

1

Tema Monopolies and Oligopolies ETF

1

Tema Luxury ETF

2

Tema Oncology ETF

2

Tema Global Royalties ETF

3

Schedule of Investments

4

Tema American Reshoring ETF

4

Tema Monopolies and Oligopolies ETF

5

Tema Luxury ETF

6

Tema Oncology ETF

7

Tema Global Royalties ETF

8

Statements of Assets and Liabilities

9

Statements of Operations

10

Statement of Changes in Net Assets

11

Tema American Reshoring ETF

11

Tema Monopolies and Oligopolies ETF

12

Tema Luxury ETF

13

Tema Oncology ETF

14

Tema Global Royalties ETF

15

Financial Highlights

16

Notes to the Financial Statements

17

Shareholder Expense Examples

24

Board Approval of Investment Advisory Agreement and Sub-Advisory Agreement

25

Additional Information

28

 

1

Portfolio Allocations
by Sector and Country
(Unaudited)

Tema ETF Trust

August 31, 2023  

Tema American Reshoring ETF

Sector

Percentage of
Total Net Assets

Industrials

74.2%

Materials

20.5%

Consumer Discretionary

2.5%

Information Technology

2.1%

Money Market Fund and Other Assets and Liabilities

0.7%

Total

100.0%

Country

Percentage of
Total Net Assets

United States

74.1%

Ireland

17.9%

Switzerland

2.7%

United Kingdom

2.5%

Singapore

1.2%

Taiwan

0.9%

Other(1) 

0.7%

Total

100.0%

Tema Monopolies and Oligopolies ETF

Sector

Percentage of
Total Net Assets

Industrials

39.2%

Financials

24.7%

Health Care

12.7%

Information Technology

12.2%

Materials

6.5%

Communication Services

2.6%

Money Market Fund and Other Assets and Liabilities

2.1%

Total

100.0%

 

Country

Percentage of
Total Net Assets

United States

53.2%

Netherlands

10.9%

France

9.4%

Canada

9.1%

Spain

4.4%

Denmark

3.5%

Germany

3.2%

Switzerland

2.2%

United Kingdom

2.0%

Other(1) 

2.1%

Total

100.0%

(1) Includes cash and net other assets (liabilities).

 

2

Portfolio Allocations
by Sector and Country
(Unaudited) (Continued)

Tema ETF Trust

August 31, 2023  

Tema Luxury ETF

Sector

Percentage of
Total Net Assets

Consumer Discretionary

59.9%

Consumer Staples

19.0%

Health Care

1.4%

Money Market Fund and Other Assets and Liabilities

19.7%

Total

100.0%

Country

Percentage of
Total Net Assets

France

30.5%

United States

12.9%

Germany

8.7%

Italy

7.7%

Switzerland

7.5%

Netherlands

5.6%

China

2.6%

Cayman Islands

2.5%

United Kingdom

1.5%

Virgin Islands (British)

0.8%

Other(1) 

19.7%

Total

100.0%

Tema Oncology ETF

Sector

Percentage of
Total Net Assets

Health Care

99.4%

Money Market Fund and Other Assets and Liabilities

0.6%

Total

100.0%

Country

Percentage of
Total Net Assets

United States

61.8%

Japan

6.5%

Switzerland

6.3%

United Kingdom

6.1%

Cayman Islands

5.8%

Netherlands

5.5%

Germany

3.6%

Denmark

2.8%

Canada

1.0%

Other(1) 

0.6%

Total

100.0%

(1)Includes cash and net other assets (liabilities).

 

3

Tema Global Royalties ETF

Sector

Percentage of
Total Net Assets

Materials

36.5%

Energy

27.9%

Information Technology

12.3%

Health Care

10.3%

Communication Services

8.6%

Money Market Fund and Other Assets and Liabilities

4.4%

Total

100.0%

 

Country

Percentage of
Total Net Assets

Canada

40.3%

United States

40.2%

United Kingdom

4.8%

Australia

3.8%

Netherlands

3.7%

Denmark

2.8%

Other(1) 

4.4%

Total

100.0%

(1)Includes cash and net other assets (liabilities).

Portfolio Allocations
by Sector and Country
(Unaudited) (Continued)

Tema ETF Trust

August 31, 2023  

The accompanying notes are an integral part of these financial statements.

 

4

Schedule of Investments

Tema American Reshoring ETF

August 31, 2023 (Unaudited)

Investments

Number of Shares

 

Value

 

COMMON STOCKS — 99.3% 

Aerospace & Defense — 2.9% 

Boeing Co. (The)*

1,368

$306,473

Air Freight & Logistics — 3.1% 

GXO Logistics, Inc.*

5,040

322,409

Building Products — 2.7% 

Allegion plc - ADR^

2,484

282,704

Chemicals — 4.5% 

Linde plc - ADR^

1,224

473,737

Commercial Services & Supplies — 3.1% 

Clean Harbors, Inc.*

1,944

329,197

Construction & Engineering — 5.5% 

API Group Corp.*

8,136

229,028

Fluor Corp.*

9,900

346,401

 

575,429

Construction Materials — 12.9% 

CRH plc - SP - ADR^

9,108

524,347

Summit Materials, Inc., Class A*

8,856

331,303

Vulcan Materials Co. 

2,304

502,848

 

1,358,498

Electrical Equipment — 16.1% 

ABB Ltd.^

7,452

284,211

Eaton Corp. plc - ADR^

2,628

605,412

Emerson Electric Co. 

3,204

314,793

Rockwell Automation, Inc. 

1,584

494,335

 

1,698,751

Electronic Equipment, Instruments
& Components — 1.1% 

Flex Ltd. - ADR*^

4,320

119,189

Ground Transportation — 2.8% 

Union Pacific Corp. 

1,332

293,799

Hotels, Restaurants & Leisure — 2.5% 

Compass Group plc^

10,394

262,421

Machinery — 23.9% 

Caterpillar, Inc. 

1,224

344,103

Federal Signal Corp. 

5,076

309,382

Ingersoll Rand, Inc. 

4,572

318,257

Lincoln Electric Holdings, Inc. 

1,584

304,857

Parker-Hannifin Corp. 

792

330,185

SPX Technologies, Inc.*

3,744

295,851

Terex Corp. 

5,652

342,568

Timken Co. (The) 

3,528

269,610

 

2,514,813

Metals & Mining — 3.1% 

ATI, Inc.*

7,128

323,112

Investments

Number of Shares

 

Value

 

Semiconductors & Semiconductor Equipment — 0.9% 

Taiwan Semiconductor Manufacturing Co., Ltd. - ADR^

1,044

$97,687

Trading Companies & Distributors — 14.2% 

Applied Industrial Technologies, Inc. 

3,456

533,503

Fastenal Co. 

4,968

286,057

Herc Holdings, Inc. 

2,628

342,008

WESCO International, Inc. 

2,052

332,116

 

1,493,684

TOTAL COMMON STOCKS
(Cost $9,398,527)

10,451,903

 

SHORT-TERM INVESTMENTS — 0.7%

Money Market Fund 

First American Treasury Obligations Fund - Class X, 5.261% (a)

77,203

77,203

TOTAL SHORT-TERM INVESTMENTS
(Cost $77,203)

77,203

 

TOTAL INVESTMENTS
(Cost $9,475,730) — 100.0%

10,529,106

OTHER ASSETS LESS
LIABILITIES — 0.0% (b)

4,623

NET ASSETS — 100.0%

$10,533,729

*Non-income producing security.

^Foreign security.

(a)7-day net yield.

(b)Represents less than 0.05%.

ADR - American Depositary Receipt

plc - Public Limited Company

SP - ADR - Sponsored American Depositary Receipt

The Global Industry Classification Standard (GICS®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.

The accompanying notes are an integral part of these financial statements.

 

5

Schedule of Investments

Tema Monopolies and Oligopolies ETF

August 31, 2023 (Unaudited) 

Investments

Number of Shares

 

Value

 

COMMON STOCKS — 97.9% 

Aerospace & Defense — 10.2% 

Airbus SE^

2,232

$327,656

Safran S.A.^

1,968

316,473

 

644,129

Capital Markets — 19.7% 

CME Group, Inc. 

960

194,573

Intercontinental Exchange, Inc. 

2,232

263,354

Moody’s Corp. 

960

323,328

MSCI, Inc. 

240

130,469

S&P Global, Inc. 

840

328,322

 

1,240,046

Chemicals — 3.3% 

Sherwin-Williams Co. (The) 

768

208,681

Commercial Services & Supplies — 3.2% 

Copart, Inc.*

4,512

202,273

Construction & Engineering — 7.3% 

Ferrovial SE^

5,670

179,837

Vinci S.A.^

2,472

275,986

 

455,823

Construction Materials — 3.2% 

Vulcan Materials Co. 

912

199,044

Diversified Telecommunication Services — 2.6% 

Cellnex Telecom S.A.^ (a)

4,296

164,441

Financial Services — 5.0% 

Visa, Inc., Class A  

1,272

312,505

Ground Transportation — 9.1% 

Canadian National
Railway Co. - ADR^

2,472

278,372

Canadian Pacific
Kansas City Ltd. - ADR^

3,696

293,388

 

571,760

Health Care Equipment & Supplies — 7.0% 

Alcon, Inc.^

1,608

134,560

Carl Zeiss Meditec AG^

888

88,317

Coloplast A/S, Class B^

816

93,222

IDEXX Laboratories, Inc.*

240

122,738

 

438,837

Life Sciences Tools & Services — 1.9% 

Thermo Fisher Scientific, Inc. 

216

120,334

Machinery — 3.7% 

Knorr-Bremse AG^

1,680

114,950

Otis Worldwide Corp. 

1,392

119,086

 

234,036

Pharmaceuticals — 3.8% 

Merck & Co., Inc. 

1,008

109,852

Novo Nordisk A/S, Class B^

696

129,011

238,863

Investments

Number of Shares

 

Value

 

Professional Services — 3.9% 

Equifax, Inc. 

576

$119,059

RELX plc^

3,888

126,975

 

246,034

Semiconductors & Semiconductor Equipment — 5.2% 

ASML Holding N.V.^

264

174,023

Lam Research Corp. 

216

151,718

 

325,741

Software — 7.0% 

Fair Isaac Corp.*

240

217,102

Intuit, Inc. 

408

221,058

 

438,160

Transportation Infrastructure — 1.8% 

Aena SME S.A.*^ (a)

722

113,521

TOTAL COMMON STOCKS
(Cost $5,912,380)

6,154,228

 

SHORT-TERM INVESTMENTS — 2.1%

Money Market Fund 

First American Treasury Obligations Fund - Class X, 5.261% (b)

132,788

132,788

SHORT-TERM INVESTMENTS
(Cost $132,788)

132,788

 

TOTAL INVESTMENTS
(Cost $6,045,168) — 100.0%

6,287,016

OTHER ASSETS LESS
LIABILITIES — 0.0% (c)

997

NET ASSETS — 100.0%

$6,288,013

*Non-income producing security.

^Foreign security.

(a)Securities purchased pursuant to Rule 144A of the Securities Act of 1933, as amended, and may be sold only to dealers in that program or other “qualified institutional buyers.” These securities have been deemed to be liquid by the Fund’s adviser under the supervision of the Board of Trustees. As of August 31, 2023, the value of these investments was $277,962 or 4.4% of total net assets.

(b)7-day net yield.

(c)Represents less than 0.05%.

ADR - American Depositary Receipt

plc - Public Limited Company

The Global Industry Classification Standard (GICS®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.

The accompanying notes are an integral part of these financial statements.

 

6

Schedule of Investments

Tema Luxury ETF

August 31, 2023 (Unaudited)

Investments

Number of Shares

 

Value

 

COMMON STOCKS — 78.9% 

Automobiles — 9.8% 

Bayerische Motoren Werke AG^

2,178

$229,488

Ferrari N.V. - ADR^

759

241,165

Mercedes-Benz Group AG^

3,993

292,436

 

763,089

Beverages — 10.3% 

Davide Campari-Milano N.V.^

15,015

196,518

Kweichow Moutai Co. Ltd., Class A^

800

202,683

Pernod Ricard S.A.^

1,291

253,662

Remy Cointreau S.A.^

990

153,458

 

806,321

Health Care Equipment & Supplies — 1.4% 

EssilorLuxottica S.A.^

563

106,164

Hotels, Restaurants & Leisure — 11.1% 

Hilton Worldwide Holdings, Inc. 

1,584

235,462

Las Vegas Sands Corp. 

2,277

124,916

Marriott International, Inc., Class A  

1,386

282,065

MGM Resorts International 

3,465

152,391

Wynn Resorts Ltd. 

726

73,602

 

868,436

Leisure Products — 3.4% 

Sanlorenzo S.p.A./Ameglia^

6,600

265,514

Personal Care Products — 8.7% 

L’Oréal S.A.^

1,551

682,486

Specialty Retail — 2.5% 

Chow Tai Fook Jewellery Group Ltd.^

69,003

104,705

Farfetch Ltd., Class A - ADR*^

33,146

94,466

 

199,171

Textiles, Apparel & Luxury Goods — 31.7% 

Brunello Cucinelli S.p.A.^

1,452

120,290

Burberry Group plc^

4,191

115,952

Capri Holdings Ltd. - ADR*^

1,220

64,038

Cie Financiere Richemont S.A.^

4,125

586,517

Hermes International SCA^

251

517,345

Hugo Boss AG^

660

49,739

LVMH Moet Hennessy
Louis Vuitton SE^

792

671,758

Moncler S.p.A.^

2,508

170,353

Prada S.p.A.^

7,095

46,366

Ralph Lauren Corp. 

528

61,581

Tapestry, Inc. 

2,409

80,268

 

2,484,207

TOTAL COMMON STOCKS
(Cost $6,420,954)

6,175,388

Investments

Number of Shares

 

Value

 

PREFERRED STOCKS — 1.4% 

Automobiles — 1.4%

Dr. Ing. h.c. F. Porsche AG^ (a)

990

$109,337

TOTAL PREFERRED STOCKS
(Cost $120,768)

109,337

 

SHORT-TERM INVESTMENTS — 19.7%

Money Market Fund

First American Treasury Obligations Fund - Class X, 5.261% (b)

1,539,362

1,539,362

TOTAL SHORT-TERM INVESTMENTS
(Cost $1,539,362)

1,539,362

 

TOTAL INVESTMENTS
(Cost $8,081,084) — 100.0%

7,824,087

OTHER ASSETS LESS
LIABILITIES — 0.0% (c)

2,749

NET ASSETS — 100.0%

$7,826,836

*Non-income producing security.

^Foreign security.

(a)Securities purchased pursuant to Rule 144A of the Securities Act of 1933, as amended, and may be sold only to dealers in that program or other “qualified institutional buyers.” These securities have been deemed to be liquid by the Fund’s adviser under the supervision of the Board of Trustees. As of August 31, 2023, the value of these investments was $109,337 or 1.4% of total net assets.

(b)7-day net yield.

(c)Represents less than 0.05%.

ADR - American Depositary Receipt

plc - Public Limited Company

The Global Industry Classification Standard (GICS®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.

The accompanying notes are an integral part of these financial statements.

 

7

Schedule of Investments

Tema Oncology ETF

August 31, 2023 (Unaudited) 

Investments

Number of Shares

 

Value

 

COMMON STOCKS — 99.4% 

Biotechnology — 58.3% 

Agios Pharmaceuticals, Inc.*

1,287

$35,302

Ambrx Biopharma, Inc. - ADR*^

792

11,183

Arcellx, Inc.*

648

23,224

Arcus Biosciences, Inc.*

1,242

25,461

Argenx SE - ADR*^

135

67,836

BeiGene Ltd. - ADR*^

333

69,114

Celldex Therapeutics, Inc.*

2,025

56,497

Cogent Biosciences, Inc.*

2,376

29,011

CRISPR Therapeutics AG - ADR*^

882

44,109

Cullinan Oncology, Inc.*

2,169

22,449

CureVac N.V. - ADR*^

3,834

34,238

Day One Biopharmaceuticals, Inc.*

1,710

23,068

Deciphera Pharmaceuticals, Inc.*

1,629

22,871

Exact Sciences Corp.*

612

51,206

Exelixis, Inc.*

2,727

61,058

Fusion Pharmaceuticals, Inc. - ADR*^

7,497

22,341

Genmab A/S - ADR*^

1,629

62,374

Gilead Sciences, Inc. 

765

58,507

Immunocore Holdings plc - ADR*^

522

29,373

ImmunoGen, Inc.*

3,906

61,871

Incyte Corp.*

1,026

66,208

Intellia Therapeutics, Inc.*

1,116

41,828

Legend Biotech Corp. - ADR*^

720

49,939

Mereo Biopharma Group plc - ADR*^

17,712

24,265

Merus N.V. - ADR*^

981

21,945

Mirati Therapeutics, Inc.*

1,368

50,890

MorphoSys AG*^

1,116

33,847

Regeneron Pharmaceuticals, Inc.*

135

111,576

Relay Therapeutics, Inc.*

3,015

30,813

Revolution Medicines, Inc.*

945

32,102

Syndax Pharmaceuticals, Inc.*

900

16,659

Zentalis Pharmaceuticals, Inc.*

873

23,187

 

1,314,352

Health Care Equipment & Supplies — 3.6% 

Lantheus Holdings, Inc.*

486

33,262

Siemens Healthineers AG^ (a)

954

47,844

 

81,106

Health Care Providers & Services — 4.7% 

Guardant Health, Inc.*

1,539

60,144

Option Care Health, Inc.*

1,314

45,767

 

105,911

Health Care Technology — 3.9% 

Schrodinger, Inc.*

1,404

51,793

Veeva Systems, Inc., Class A*

171

35,688

 

87,481

Life Sciences Tools & Services — 5.5% 

10X Genomics, Inc., Class A*

855

44,332

Illumina, Inc.*

486

80,297

124,629

Investments

Number of Shares

 

Value

 

Pharmaceuticals — 23.4% 

Arvinas, Inc.*

936

$26,405

AstraZeneca plc^

630

85,092

Bristol-Myers Squibb Co. 

1,107

68,247

Chugai Pharmaceutical Co. Ltd.^

1,899

58,173

Daiichi Sankyo Co. Ltd.^

2,988

88,288

Merck & Co., Inc. 

954

103,967

Novartis AG^

972

98,273

 

528,445

TOTAL COMMON STOCKS
(Cost $2,234,216)

2,241,924

 

SHORT-TERM INVESTMENTS — 0.6%

Money Market Fund 

First American Treasury Obligations Fund - Class X, 5.261% (b)

13,027

13,027

TOTAL SHORT-TERM INVESTMENTS
(Cost $13,027)

13,027

 

TOTAL INVESTMENTS
(Cost $2,247,243) — 100.0%

2,254,951

LIABILITIES IN EXCESS OF
OTHER ASSETS — (0.0)% (c)

(345

)

NET ASSETS — 100.0%

$2,254,606

*Non-income producing security.

^Foreign security.

(a)Securities purchased pursuant to Rule 144A of the Securities Act of 1933, as amended, and may be sold only to dealers in that program or other “qualified institutional buyers.” These securities have been deemed to be liquid by the Fund’s adviser under the supervision of the Board of Trustees. As of August 31, 2023, the value of these investments was $47,844 or 2.1% of total net assets.

(b)7-day net yield.

(c)Represents less than 0.05%.

ADR - American Depositary Receipt

plc - Public Limited Company

The Global Industry Classification Standard (GICS®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.

The accompanying notes are an integral part of these financial statements.

 

8

Schedule of Investments

Tema Global Royalties ETF

August 31, 2023 (Unaudited)

Investments

Number of Shares

 

Value

 

COMMON STOCKS — 95.6% 

Biotechnology — 2.8% 

Genmab A/S*^

133

$51,087

Entertainment — 8.6% 

Universal Music Group N.V.^

2,688

66,718

Warner Music Group Corp., Class A  

2,639

87,879

 

154,597

Metals & Mining — 36.5% 

Altius Minerals Corp.*^

5,880

95,911

Deterra Royalties Ltd.^

23,821

68,685

Franco-Nevada Corp. - ADR^

637

91,702

Labrador Iron Ore Royalty Corp.*^

2,324

54,024

Osisko Gold Royalties Ltd.*

3,977

53,156

Royal Gold, Inc. 

462

51,786

Sandstorm Gold Ltd. - ADR^

17,262

94,941

Triple Flag Precious Metals
Corp. - ADR^

3,927

53,957

Wheaton Precious Metals
Corp. - ADR^

2,121

92,433

 

656,595

Oil, Gas & Consumable Fuels — 27.9% 

Black Stone Minerals LP 

2,968

51,495

Freehold Royalties Ltd.*^

4,858

51,701

Kimbell Royalty Partners LP 

3,500

53,725

Permian Basin Royalty Trust 

2,933

60,097

PrairieSky Royalty Ltd.*

4,487

85,841

Sitio Royalties Corp., Class A  

2,177

55,296

Texas Pacific Land Corp. 

49

92,353

Topaz Energy Corp.*^

3,206

51,535

 

502,043

Pharmaceuticals — 7.4% 

Ligand Pharmaceuticals, Inc.*

742

48,801

Royalty Pharma plc, Class A - ADR^

2,863

85,375

 

134,176

Semiconductors & Semiconductor Equipment — 3.0% 

Qualcomm, Inc. 

470

53,829

Software — 9.4% 

Dolby Laboratories, Inc., Class A  

903

76,276

InterDigital, Inc. 

1,064

92,259

 

168,535

TOTAL COMMON STOCKS
(Cost $1,691,296)

1,720,862

Investments

Number of Shares

 

Value

 

SHORT-TERM INVESTMENTS — 4.3%

Money Market Fund

First American Treasury Obligations Fund - Class X, 5.261% (a)

76,557

$76,557

TOTAL SHORT-TERM INVESTMENTS
(Cost $76,557)

76,557

 

TOTAL INVESTMENTS
(Cost $1,767,853) — 99.9%

1,797,419

OTHER ASSETS LESS
LIABILITIES — 0.1% 

2,442

NET ASSETS — 100.0%

$1,799,861

*Non-income producing security.

^Foreign security.

(a)7-day net yield.

ADR - American Depositary Receipt

plc - Public Limited Company

The Global Industry Classification Standard (GICS®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.

The accompanying notes are an integral part of these financial statements.

 

9

Statements of Assets and Liabilities

Tema ETF Trust

August 31, 2023 (Unaudited)

Tema
American Reshoring
ETF

Tema Monopolies and Oligopolies ETF

Tema
Luxury
ETF

Tema
Oncology
ETF

Tema
Global Royalties
ETF

ASSETS: 

Investments in securities, at value(1)
(See Note 2) 

$10,451,903

$6,154,228

$6,284,725

$2,241,924

$1,720,862

Investments in money market fund, at value(2)
(See Note 2) 

77,203

132,788

1,539,362

13,027

76,557

Total investments, at value (See Note 2) 

10,529,106

6,287,016

7,824,087

2,254,951

1,797,419

Receivables: 

Dividends and interest 

10,814

4,824

7,323

17

2,648

Foreign tax reclaims 

126

264

120

Total Assets 

10,539,920

6,291,966

7,831,674

2,254,968

1,800,187

 

LIABILITIES: 

Payables: 

Investment management fees 

6,191

3,953

4,838

362

326

Total Liabilities 

6,191

3,953

4,838

362

326

NET ASSETS 

$10,533,729

$6,288,013

$7,826,836

$2,254,606

$1,799,861

 

NET ASSETS CONSIST OF: 

Paid-in capital 

$9,469,941

$6,039,465

$8,057,310

$2,247,243

$1,767,625

Distributable earnings (accumulated loss) 

1,063,788

248,548

(230,474

)

7,363

32,236

NET ASSETS 

$10,533,729

$6,288,013

$7,826,836

$2,254,606

$1,799,861

 

Share issued and outstanding, $0 par value, unlimited shares authorized 

360,000

240,000

330,000

90,000

70,000

 

Net Asset Value, Per Share 

$29.26

$26.20

$23.72

$25.05

$25.71

 

(1)Investments in securities, at identified cost

$9,398,527

$5,912,380

$6,541,722

$2,234,216

$1,691,296

(2)Investments in money market fund, at identified cost

77,203

132,788

1,539,362

13,027

76,557

Total investments, at identified cost 

$9,475,730

$6,045,168

$8,081,084

$2,247,243

$1,767,853

The accompanying notes are an integral part of these financial statements.

 

10

Statements of Operations

Tema ETF Trust

For the Period Ended August 31, 2023 (Unaudited)

Tema
American
Reshoring
ETF
(a) 

Tema
Monopolies
and
Oligopolies
ETF
(a) 

Tema
Luxury
ETF
(a) 

Tema
Oncology
ETF
(b) 

Tema
Global
Royalties
ETF
(c) 

INVESTMENT INCOME: 

Dividends 

$26,304

$15,473

$24,617

$

$3,067

Interest 

918

1,802

11,028

16

109

Foreign withholding tax on dividends 

(72

)

(900

)

(1,817

)

(179

)

Total investment income

27,150

16,375

33,828

16

2,997

 

EXPENSES: 

Investment management fees (See Note 3) 

22,402

15,977

18,589

477

430

Total expenses before adjustments

22,402

15,977

18,589

477

430

Less: waivers by Adviser (Note 3) 

(5,431

)

(3,873

)

(4,506

)

(116

)

(104

)

Total expenses after adjustments

16,971

12,104

14,083

361

326

Net Investment Income (Loss) 

10,179

4,271

19,745

(345

)

2,671

 

REALIZED AND UNREALIZED GAIN (LOSS)
ON INVESTMENTS: 

Net realized gain (loss) on: 

Investments in securities 

6,552

In-kind redemptions 

Foreign currency transactions 

233

2,429

226

(1

)

Net realized gain (loss)  

233

2,429

6,778

(1

)

Change in net unrealized appreciation
(depreciation) on: 

Investments in securities 

1,045,937

239,711

(262,955

)

8,532

28,947

Translation of assets and liabilities denominated in foreign currencies 

7,439

2,137

5,958

(824

)

619

Change in net unrealized appreciation (depreciation)  

1,053,376

241,848

(256,997

)

7,708

29,566

Net realized and unrealized gain (loss) 

1,053,609

244,277

(250,219

)

7,708

29,565

Net increase (decrease) in net assets resulting from operations 

$1,063,788

$248,548

$(230,474

)

$7,363

$32,236

(a)The Fund commenced investment operations on May 11, 2023.

(b)The Fund commenced investment operations on August 15, 2023.

(c)The Fund commenced investment operations on August 17, 2023.

The accompanying notes are an integral part of these financial statements.

 

11

Statement of Changes in Net Assets

Tema American Reshoring ETF

For the
Period Ended August 31, 2023 (Unaudited)
(a) 

OPERATIONS: 

Net investment income (loss) 

$10,179

Net realized gain (loss)  

233

Net change in unrealized appreciation (depreciation) 

1,053,376

Net increase (decrease) in net assets resulting from operations 

1,063,788

 

DISTRIBUTIONS TO SHAREHOLDERS: 

Distributions from distributable earnings  

Total distributions 

 

CAPITAL TRANSACTIONS: 

Proceeds from shares issued 

9,468,544

(b) 

Cost of shares redeemed 

(100,000

)(b) 

Variable ETF transaction fees (Note 7) 

1,397

Net increase (decrease) from capital transactions 

9,369,941

Total increase (decrease) in net assets 

10,433,729

 

NET ASSETS: 

Beginning of period 

100,000

(b) 

End of period 

$10,533,729

 

SHARE TRANSACTIONS: 

Beginning of period 

4,000

(b) 

Shares issued 

360,000

Shares redeemed 

(4,000

)(b) 

Shares Outstanding, End of Period 

360,000

(a)The Fund commenced investment operations on May 11, 2023.

(b)Beginning capital of $100,000 was contributed by NEOS Investment Management LLC, investment sub-adviser to the Fund, in exchange for 4,000 Shares of the Fund in connection with the seeding of the Trust. The shares were redeemed by the investment sub-adviser on May 16, 2023.

The accompanying notes are an integral part of these financial statements.

 

12

Statement of Changes in Net Assets

Tema Monopolies and Oligopolies ETF

 

For the
Period Ended August 31, 2023 (Unaudited)
(a) 

OPERATIONS: 

Net investment income (loss) 

$4,271

Net realized gain (loss)  

2,429

Net change in unrealized appreciation (depreciation) 

241,848

Net increase (decrease) in net assets resulting from operations 

248,548

 

DISTRIBUTIONS TO SHAREHOLDERS: 

Distributions from distributable earnings  

Total distributions 

 

CAPITAL TRANSACTIONS: 

Proceeds from shares issued 

6,039,465

Cost of shares redeemed 

Variable ETF transaction fees (Note 7) 

Net increase (decrease) from capital transactions 

6,039,465

Total increase (decrease) in net assets 

6,288,013

 

NET ASSETS: 

Beginning of period 

End of period 

$6,288,013

 

SHARE TRANSACTIONS: 

Beginning of period 

Shares issued 

240,000

Shares redeemed 

Shares Outstanding, End of Period 

240,000

(a)The Fund commenced investment operations on May 11, 2023.

The accompanying notes are an integral part of these financial statements.

 

13

Statement of Changes in Net Assets

Tema Luxury ETF

For the
Period Ended August 31, 2023 (Unaudited)
(a) 

OPERATIONS: 

Net investment income (loss) 

$19,745

Net realized gain (loss)  

6,778

Net change in unrealized appreciation (depreciation) 

(256,997

)

Net increase (decrease) in net assets resulting from operations 

(230,474

)

 

DISTRIBUTIONS TO SHAREHOLDERS: 

Distributions from distributable earnings  

Total distributions 

 

CAPITAL TRANSACTIONS: 

Proceeds from shares issued 

8,053,761

Cost of shares redeemed 

Variable ETF transaction fees (Note 7) 

3,549

Net increase (decrease) from capital transactions 

8,057,310

Total increase (decrease) in net assets 

7,826,836

 

NET ASSETS: 

Beginning of period 

End of period 

$7,826,836

 

SHARE TRANSACTIONS: 

Beginning of period 

Shares issued 

330,000

Shares redeemed 

Shares Outstanding, End of Period 

330,000

(a)The Fund commenced investment operations on May 11, 2023.

The accompanying notes are an integral part of these financial statements.

 

14

Statement of Changes in Net Assets

Tema Oncology ETF

 

For the
Period Ended August 31, 2023 (Unaudited)
(a) 

OPERATIONS: 

Net investment income (loss) 

$(345

)

Net realized gain (loss)  

Net change in unrealized appreciation (depreciation) 

7,708

Net increase (decrease) in net assets resulting from operations 

7,363

 

DISTRIBUTIONS TO SHAREHOLDERS: 

Distributions from distributable earnings  

Total distributions 

 

CAPITAL TRANSACTIONS: 

Proceeds from shares issued 

2,247,243

Cost of shares redeemed 

Variable ETF transaction fees (Note 7) 

Net increase (decrease) from capital transactions 

2,247,243

Total increase (decrease) in net assets 

2,254,606

 

NET ASSETS: 

Beginning of period 

End of period 

$2,254,606

 

SHARE TRANSACTIONS: 

Beginning of period 

Shares issued 

90,000

Shares redeemed 

Shares Outstanding, End of Period 

90,000

(a)The Fund commenced investment operations on August 15, 2023.

The accompanying notes are an integral part of these financial statements.

 

15

Statement of Changes in Net Assets

Tema Global Royalties ETF

For the
Period Ended August 31, 2023 (Unaudited)
(a) 

OPERATIONS: 

Net investment income (loss) 

$2,671

Net realized gain (loss)  

(1

)

Net change in unrealized appreciation (depreciation) 

29,566

Net increase (decrease) in net assets resulting from operations 

32,236

 

DISTRIBUTIONS TO SHAREHOLDERS: 

Distributions from distributable earnings  

Total distributions 

 

CAPITAL TRANSACTIONS: 

Proceeds from shares issued 

1,767,625

Cost of shares redeemed 

Variable ETF transaction fees (Note 7) 

Net increase (decrease) from capital transactions 

1,767,625

Total increase (decrease) in net assets 

1,799,861

 

NET ASSETS: 

Beginning of period 

End of period 

$1,799,861

 

SHARE TRANSACTIONS: 

Beginning of period 

Shares issued 

70,000

Shares redeemed 

Shares Outstanding, End of Period 

70,000

(a)The Fund commenced investment operations on August 17, 2023.

The accompanying notes are an integral part of these financial statements.

 

16

Financial Highlights

Tema ETF Trust

For a share outstanding for the periods presented (Unaudited)

Net asset value, beginning of period

Net investment income (loss)(a) 

Net realized and unrealized gain (loss)

Total from investment operations

Distributions from net investment income

Total distributions

Transaction fees(g) 

Net asset value, end of period

Total
Return -
Net Asset Value
(b) 

Total Return- Market Value(c) 

Net Assets, End of Period (000’s)

Expenses, before waivers(d) 

Expenses, after waivers(d) 

Net investment income (loss), before waivers(d) 

Net investment income (loss), after waivers(d) 

Portfolio Turnover Rate(e) 

Tema American Reshoring ETF

May 11, 2023(f) to August 31, 2023

$25.00

$0.04

$4.21

$4.25

$

$

$0.01

$29.26

17.04

%

17.69

%

$10,534

0.99

%

0.75

%

0.21

%

0.45

%

%

Tema Monopolies and Oligopolies ETF

May 11, 2023(f) to August 31, 2023

$ 25.00

0.02

1.18

1.20

26.20

4.80

5.17

6,288

0.99

0.75

0.02

0.26

Tema Luxury ETF

May 11, 2023(f) to August 31, 2023

$ 25.00

0.08

(1.37

)

(1.29

)

0.01

23.72

-5.13

-4.59

7,827

0.99

0.75

0.81

1.05

28

Tema Oncology ETF

August 15, 2023(f) to August 31, 2023

$ 25.12

(0.01

)

(0.06

)

(0.07

)

25.05

-0.27

-0.17

2,255

0.99

0.75

(0.96

)

(0.72

)

Tema Global Royalties ETF

August 17, 2023(f) to August 31, 2023

$ 25.00

0.06

0.65

0.71

25.71

2.85

3.08

1,800

0.99

0.75

5.91

6.15

(a)Calculated using average shares outstanding, during the period.

(b)Net asset value total return is calculated assuming an initial investment made at the net asset value at the beginning of the period, reinvestment of all dividends and distributions at net asset value during the period and redemption on the last day of the period at net asset value.

(c)Market value total return is calculated assuming an initial investment made at market value at the beginning of the period, reinvestment of all dividends and distributions at market value during the period and redemption on the last day of the period at market value. The market value is based upon the official closing price at 4:00 p.m. from either the CBOE BZX Exchange, Inc., NASDAQ Stock Market LLC or NYSE Arca, Inc. Exchange. Market value returns may vary from net asset value returns.

(d)For periods of less than one year, these ratios are annualized.

(e)Portfolio turnover is not annualized and calculation excludes in-kind transactions.

(f)Commencement of operations.

(g)Includes transaction fees associated with the issuance and redemption of Creation Units.

 

17

Notes to the Financial Statements

Tema ETF Trust

August 31, 2023 (Unaudited)

NOTE 1 – ORGANIZATION

The Tema ETF Trust (the “Trust”) was organized as a Delaware statutory trust on July 25, 2022 and is authorized to issue multiple series or portfolios. The Trust is an open-end investment company, registered under the Investment Company Act of 1940, as amended (the “1940 Act”). The Trust currently consists of five operational exchange-traded funds (“ETFs”): Tema American Reshoring ETF (“RSHO”), Tema Monopolies and Oligopolies ETF (“TOLL”), Tema Luxury ETF (“LUX”), Tema Oncology ETF (“CANC”), and Tema Global Royalties ETF (“ROYA”), (collectively, the “Funds” or individually, a “Fund”). The Funds are each non-diversified management investment companies under the 1940 Act. The investment objective of RSHO, TOLL, LUX, CANC and ROYA is to seek to provide long-term growth.

Tema Global Limited (the “Adviser”) is the investment adviser to each Fund.

NEOS Investment Management, LLC acts as the sub-adviser to each Fund.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Trust, which is an investment company, follows accounting and reporting guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Topic 946, “Financial Services — Investment Companies.”

The following is a summary of significant accounting policies consistently followed by the Funds in the preparation of their financial statements. These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

A. Investment Valuation. The net asset value (“NAV”) of each Fund’s shares is calculated each business day as of the close of regular trading on the New York Stock Exchange (“NYSE”), generally 4:00 p.m., Eastern Time. NAV per share is computed by dividing the net assets of each Fund by each Fund’s number of shares outstanding.

When calculating the NAV of each Fund’s shares, securities held by the Funds are valued at market quotations when reliable market quotations are readily available. Exchange traded securities and instruments (including equity securities, depositary receipts and ETFs) are generally valued at the last reported sale price on the principal exchange on which such securities are traded (at the NASDAQ Official Closing Price for NASDAQ listed securities), as of the close of regular trading on the NYSE on the day the securities are being valued or, if there are no sales, at the mean of the most recent bid and asked prices. Over-the-counter securities and instruments not traded on an exchange are generally valued at the last traded price. Investments in open-end regulated investment companies are valued at NAV. In the absence of a recorded transaction sale price; or if the last sale price is unavailable, securities are valued at the mean between last bid and ask, as quoted. If an ask price is unavailable, the last bid price is used. Such valuations would typically be categorized as Level 1 or Level 2 in the fair value hierarchy described below.

When reliable market quotations are not readily available, securities are priced at their fair value as determined in good faith by the Adviser in accordance with the Trust’s valuation guidelines. Pursuant to Rule 2a-5 under the 1940 Act, each Fund has designated the Adviser as its “Valuation Designee” to perform all of the fair value determinations as well as to perform all of the responsibilities that may be performed by the Valuation Designee in accordance with Rule 2a-5. The Valuation Designee is authorized to make all necessary determinations of the fair values of portfolio securities and other assets for which market quotations are not readily available or if it is deemed that the prices obtained from brokers and dealers or independent pricing services are unreliable. The Funds may use fair value pricing in a variety of circumstances, including but not limited to, situations when the value of a security has been materially affected by events occurring after the close of the market on which such security is principally traded (such as a corporate action or other news that may materially affect the price of such security) or trading in such security has been suspended or halted. Such valuations would typically be categorized as Level 2 or Level 3 in the fair value hierarchy described below. Fair value pricing involves subjective judgments and it is possible that a fair value determination for a security is materially different than the value that could be realized upon the sale of such security. As of August 31, 2023, there were no securities internally fair valued and/or valued using a Level 3 valuation.

The Funds disclose the fair value of their investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Funds (observable inputs) and (2) the Funds’ own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs).

 

18

Notes to the Financial Statements (Continued)

Tema ETF Trust

August 31, 2023 (Unaudited)

The three levels defined by the hierarchy are as follows:

• Level 1Quoted prices in active markets for identical assets that the Funds have the ability to access.

• Level 2Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

• Level 3Significant unobservable inputs (including the Funds’ own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value each Fund’s investments as of August 31, 2023:

Tema American Reshoring ETF

 

Level 1

 

Level 2

 

Level 3

 

Total

Investments 

Common Stocks*

$10,451,903

$

$

$10,451,903

Money Market Fund

77,203

77,203

Total Investments

$10,529,106

$

$

$10,529,106

 

Tema Monopolies and Oligopolies ETF

 

Level 1

 

Level 2

 

Level 3

 

Total

Investments 

Common Stocks*

$6,154,228

$

$

$6,154,228

Money Market Fund

132,788

132,788

Total Investments

$6,287,016

$

$

$6,287,016

 

Tema Luxury ETF

 

Level 1

 

Level 2

 

Level 3

 

Total

Investments 

Common Stocks*

$6,175,388

$

$

$6,175,388

Preferred Stock*

109,337

109,337

Money Market Fund

1,539,362

1,539,362

Total Investments

$7,824,087

$

$

$7,824,087

 

Tema Oncology ETF

 

Level 1

 

Level 2

 

Level 3

 

Total

Investments 

Common Stocks*

$2,241,924

$

$

$2,241,924

Money Market Fund

13,027

13,027

Total Investments

$2,254,951

$

$

$2,254,951

 

Tema Global Royalties ETF

 

Level 1

 

Level 2

 

Level 3

 

Total

Investments 

Common Stocks*

$1,720,862

$

$

$1,720,862

Money Market Fund

76,557

76,557

Total Investments

$1,797,419

$

$

$1,797,419

*See Schedule of Investments for segregation by industry.

B. Foreign Currency Translation. The books and records of the Funds are maintained in U.S. dollars. The Funds’ assets and liabilities in foreign currencies are translated into U.S. dollars at the prevailing exchange rate at the valuation date. Transactions denominated in foreign currencies are translated into U.S. dollars at the prevailing exchange rate on the date of the transaction. The Funds’ income earned and expenses incurred in foreign denominated currencies are translated into U.S. dollars at the prevailing exchange rate on the date of such activity.

 

19

Notes to the Financial Statements (Continued)

Tema ETF Trust

August 31, 2023 (Unaudited)

The Funds do not isolate that portion of the results of operations arising from changes in the foreign exchange rates on investments from the fluctuations that result from changes in the market prices of investments held or sold during the period. Accordingly, such foreign currency gains (losses) are included in the reported net realized gain (loss) on investments in securities and net change in unrealized appreciation (depreciation) on investments in securities on the Statements of Operations.

Net realized gains (losses) on foreign currency transactions reported on the Statements of Operations arise from sales of foreign currency, including foreign exchange contracts, net currency gains and losses realized between the trade and settlement dates on securities transactions and the difference in the amounts of dividends and foreign withholding taxes recorded on the Funds’ books and the U.S. dollar equivalent of the amounts actually received or paid. Net changes in unrealized appreciation (depreciation) on translation of assets and liabilities denominated in foreign currencies reported on the Statements of Operations arise from changes (due to the changes in the exchange rate) in the value of foreign currency and assets and liabilities (other than investments) denominated in foreign currencies, which are held at year end.

C. Use of Estimates. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement. Actual results could differ from those estimates.

D. Federal Income Taxes. Each Fund intends to qualify as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended. If so qualified, the Funds will not be subject to federal income tax to the extent each Fund distributes substantially all its taxable net investment income and net capital gains to its shareholders. Therefore, no provision for federal income tax should be required. Management of the Funds is required to determine whether a tax position taken by the Funds is more likely than not to be sustained upon examination by the applicable taxing authority. Based on its analysis, Management has concluded that there are no significant uncertain tax positions that would require recognition in the financial statements as of the fiscal period ended August 31, 2023. The Funds recognize interest and penalties, if any, related to unrecognized tax benefits as income tax expense on the Statements of Operations. Management of the Funds are required to determine whether a tax position taken by the Funds is more likely than not to be sustained upon examination by the applicable taxing authority. Based on its analysis, Management has concluded that the Funds do not have any unrecognized tax benefits or uncertain tax positions that would require a provision for income tax. Accordingly, the Funds did not incur any interest or penalties for the period ended August 31, 2023.

E. Distributions to Shareholders. Each Fund expects to declare and distribute all of its net investment income, if any, to shareholders as dividends at least annually. The Funds will distribute net realized capital gains, if any, annually. The Funds may distribute such income dividends and capital gains more frequently, if necessary, to reduce or eliminate federal excise or income taxes on the Funds. The amount of any distribution will vary, and there is no guarantee the Funds will pay either an income dividend or a capital gains distribution.

F. Organizational and Offering Costs. The Adviser has paid or assumed all organizational and offering expenses for the Funds.

G. Reclassification of Capital Accounts. U.S. GAAP requires that certain components of net assets relating to permanent differences be reclassified between financial and tax reporting. These reclassifications have no effect on net assets or NAV per share and are primarily due to differing book and tax treatments for in-kind redemptions. No reclassifications were made for the period ended August 31, 2023.

NOTE 3 – INVESTMENT ADVISORY AND OTHER AGREEMENTS

Management

The Adviser acts as each Fund’s investment adviser pursuant to an investment advisory agreement with the Trust (the “Investment Advisory Agreement”).

NEOS Investment Management, LLC acts as the sub-adviser to each of the Funds pursuant to investment sub-advisory agreement with the Adviser (the “Sub-Advisory-Agreement”).

Under the terms of the Investment Advisory Agreement between the Trust, on behalf of the Funds, and the Adviser, the Adviser provides investment management services to the Funds and is responsible for the day-to-day operations of the Funds, subject to the oversight of the Board of Trustees (the “Board”) and the officers of the Trust. The Adviser administers the Funds’ business affairs, provides office facilities and equipment and certain clerical, bookkeeping and administrative services. The Adviser, on behalf of the Funds, has entered into a Sub-Advisory Agreement with the Sub-Adviser. The Sub-Adviser is responsible for the day-to-day management of

 

20

Notes to the Financial Statements (Continued)

Tema ETF Trust

August 31, 2023 (Unaudited)

each Fund’s portfolio, subject to the supervision and oversight of the Adviser and the Board. The Adviser oversees the Sub-Adviser for compliance with the Funds’ investment objectives, policies, strategies and restrictions. The Board oversees the Adviser and the Sub-Adviser, establishes policies that they must follow in their advisory activities, and oversees the hiring and termination of sub-adviser recommended by the Adviser.

Pursuant to the Investment Advisory Agreement, each Fund pays the Adviser a monthly unitary management fee at an annual rate of 0.99%, based on each Fund’s average daily net assets.

Under the Investment Advisory Agreement, the Adviser has agreed to pay all expenses incurred by the Funds except for the management fee, interest, taxes, brokerage commissions and other expenses incurred in placing orders for the purchase and sale of securities and other investment instruments, acquired fund fees and expenses (“AFFE”), extraordinary expenses, and distribution fees and expenses paid by the Funds under any distribution plan adopted pursuant to Rule 12b-1 under the 1940 Act.

Pursuant to the Sub-Advisory Agreement, the Adviser compensates the Sub-Adviser out of the management fees it receives from the Funds.

The Adviser has contractually agreed to waive its fees and reimburse expenses to the extent necessary to keep total annual operating expenses of each Fund (excluding amounts payable pursuant to any plan adopted in accordance with Rule 12b-1, interest expense, taxes, brokerage commissions, other expenditures which are capitalized in accordance with generally accepted accounting principles, and extraordinary expenses) from exceeding 0.75% of the average daily net assets of each Fund until at least June 30, 2024, unless earlier terminated by the Board of Trustees (the “Board”) of Tema ETF Trust (the “Trust”) for any reason at any time. The Adviser may not terminate the fee waiver during the contractual period.

For the period ended August 31, 2023, the table below represents the amount each Fund incurred in management fees:

 

Management fees

Tema American Reshoring ETF

$22,402

Tema Monopolies and Oligopolies ETF

15,977

Tema Luxury ETF

18,589

Tema Oncology ETF

477

Tema Global Royalties ETF

430

Each Fund has agreed that it will repay the Adviser for fees and expenses waived or reimbursed for each Fund pursuant to the contractual expense limitation described above. Such repayment would increase each Fund’s expenses and would appear on the Statements of Operations as “Repayment of prior expenses waived and/or reimbursed by the Adviser.” However, repayment would only occur up to the point of each Fund’s expense cap.

Any such repayment must be made within three years from the date the expense was borne by the Adviser. Any such repayment made under any prior expense cap cannot cause each Fund’s Operating Expenses to exceed the lower of 0.75% of average daily net assets or the annual rate of daily net assets for each Fund under the terms of a prior expense cap. For the period ended August 31, 2023, the Funds did not repay expenses to the Adviser.

As of August 31, 2023, the amounts eligible for repayment and the associated period of expiration are as follows:

Expires
August 31, 2026*

Tema American Reshoring ETF

$5,431

Tema Monopolies and Oligopolies ETF

3,873

Tema Luxury ETF

4,506

Tema Oncology ETF

116

Tema Global Royalties ETF

104

*Represents total eligible recoupment available.

 

21

Notes to the Financial Statements (Continued)

Tema ETF Trust

August 31, 2023 (Unaudited)

Administrator, Custodian, Transfer Agent and Accounting Agent

U.S. Bancorp Fund Services, LLC dba U.S. Bank Global Fund Services (“Fund Services”), an indirect wholly-owned subsidiary of U.S. Bancorp, serves as the Funds’ administrator and, in that capacity performs various administrative and accounting services for the Funds. Fund Services also serves as the Funds’ fund accountant, transfer agent, dividend disbursing agent and registrar. Fund Services prepares various federal and state regulatory filings, reports and returns for the Funds, including regulatory compliance monitoring and financial reporting; prepares reports and materials to be supplied to the trustees; monitors the activities of the Funds’ custodian, transfer agent and accountants; reviews the Funds’ advisory fee expense accrual and coordinates the preparation and payment of the advisory fees. U.S. Bank, N.A., an affiliate of Fund Services, serves as the Funds’ custodian. For the period ended August 31, 2023, there were no fees incurred from the service providers described above as the Adviser bore all such costs.

Distribution and Fund Officers

Foreside Fund Services, LLC (the “Distributor”) serves as the principal underwriter for shares of the Funds and acts as each Fund’s distributor in a continuous public offering of the Funds’ shares and serves as the distributor of Creation Units for the Funds. Shares are continuously offered for sale by the Trust through the Distributor only in Creation Units, as described further in Note 7. Shares in less than Creation Units are not distributed by the Distributor. The Distributor is a broker-dealer registered under the Securities Exchange Act of 1934, as amended, and a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”).

Foreside Fund Officer Services, LLC, an affiliate of the Distributor, provides the Trust with a Chief Compliance Officer and Principal Financial Officer.

NOTE 4 – RELATED PARTIES

As of August 31, 2023, certain officers and Trustees of the Trust were also officers or employees of the Adviser or affiliated with the Distributor, and received no fees from the Trust for serving as officers.

NOTE 5 – PURCHASES AND SALES OF SECURITIES

The costs of purchases and sales of securities, excluding short-term securities and in-kind transactions, during the period ended August 31, 2023, were as follows:

 

 

Purchases

 

Sales

Tema American Reshoring ETF

$2,517,786

$

Tema Monopolies and Oligopolies ETF

1,227,664

Tema Luxury ETF

2,001,133

1,395,041

Tema Oncology ETF

Tema Global Royalties ETF

7,027

The costs of purchases and sales of in-kind transactions, during the period ended August 31, 2023, were as follows:

 

 

Purchases
In-Kind

 

Sales
In-Kind

Tema American Reshoring ETF

$6,880,741

$

Tema Monopolies and Oligopolies ETF

4,684,716

Tema Luxury ETF

5,929,079

Tema Oncology ETF

2,234,216

Tema Global Royalties ETF

1,684,268

 

22

Notes to the Financial Statements (Continued)

Tema ETF Trust

August 31, 2023 (Unaudited)

For the period ended August 31, 2023, short-term and long-term gains on in-kind transactions were as follows:

 

 

Short Term

 

Long Term

Tema American Reshoring ETF

$

$

Tema Monopolies and Oligopolies ETF

Tema Luxury ETF

Tema Oncology ETF

Tema Global Royalties ETF

NOTE 6 – TAX MATTERS

As of February 28, 2023, the Funds had not commenced operations. Tax information will be presented within the Funds’ first annual report as of February 29, 2024.

NOTE 7 – SHARE TRANSACTIONS

Each Fund currently offers one class of shares, which has no front-end sales loads, no deferred sales charges, and no redemption fees. The standard fixed transaction fees for the Tema American Reshoring ETF and Tema Global Royalties ETF are $300, Tema Monopolies and Oligopolies ETF, Tema Luxury and Tema Oncology ETF are $500, payable to the Custodian. Additionally, a variable transaction fee may be charged by the Funds of up to a maximum of 2% of the value of the Creation Units (inclusive of any transaction fees charged), for each creation or redemption. Variable transaction fees are imposed to compensate the Funds for the transaction costs associated with creation and redemption transactions. The Adviser, subject to the approval of the Board, may adjust or waive the transaction fees from time to time. The Funds may each issue an unlimited number of shares of beneficial interest, with no par value. All shares of the Funds have equal rights and privileges.

Shares of the Tema Monopolies and Oligopolies ETF and Tema Global Royalties ETF are listed and traded on the CBOE BZX Exchange, Inc., shares of the Tema Luxury ETF and Tema American Reshoring ETF are listed and traded on the NYSE Arca, Inc. and shares of the Tema Oncology ETF are traded on the NASDAQ Stock Market LLC (the “Exchanges”). Market prices for the Shares may be different from their NAV. The Funds will issue and redeem Shares on a continuous basis at NAV only in large blocks of Shares, typically 10,000 Shares, called “Creation Units.” Creation Unit transactions are conducted in exchange for the deposit or delivery of a designated basket of in-kind securities and/or cash. Once created, Shares generally will trade in the secondary market in amounts less than a Creation Unit and at market prices that change throughout the day. Except when aggregated in Creation Units, shares are not redeemable securities of the Funds. Shares of the Funds may only be purchased or redeemed by certain financial institutions (“Authorized Participants”). An Authorized Participant is either (i) a broker-dealer or other participant in the clearing process through the Continuous Net Settlement System of the National Securities Clearing Corporation (“NSCC”) or (ii) a participant in the Depository Trust Company (“DTC”) and, in each case, must have executed a Participant Agreement with the Funds’ Distributor. Most retail investors will not qualify as Authorized Participants or have the resources to buy and sell whole Creation Units. Therefore, they will be unable to purchase or redeem shares directly from the Funds. Rather, most retail investors will purchase shares in the secondary market with the assistance of a broker and will be subject to customary brokerage commissions or fees.

For the period ended August 31, 2023, the table below represents the amount of variable rate transaction fees each Fund assessed:

Variable Rate Transaction Fees

Tema American Reshoring ETF

$1,397

Tema Monopolies and Oligopolies ETF

Tema Luxury ETF

3,549

Tema Oncology ETF

Tema Global Royalties ETF

 

23

Notes to the Financial Statements (Continued)

Tema ETF Trust

August 31, 2023 (Unaudited)

NOTE 8 – BENEFICIAL OWNERSHIP

The beneficial ownership, either directly or indirectly, of more than 25% of the voting securities of a fund creates a presumption of control of the fund, under Section 2(a)(9) of the 1940 Act. As of the date of these financial statements, Tema Global Limited, the adviser to the Tema American Reshoring ETF, Tema Monopolies and Oligopolies ETF, Tema Luxury ETF, Tema Oncology ETF and Tema Global Royalties ETF, has no voting power of the shares outstanding of the Funds. Additionally, as of the date of these financial statements, NEOS Investment Management, LLC, the sub-adviser to the Tema American Reshoring ETF, Tema Monopolies and Oligopolies ETF, Tema Luxury ETF, Tema Oncology ETF and Tema Global Royalties ETF, has no voting power of the shares outstanding of the Funds.

NOTE 9 – PRINCIPAL RISKS

As with all ETFs, shareholders of the Funds are subject to the risk that their investment could lose money. The Funds are subject to the principal risks, any of which may adversely affect each Fund’s NAV, trading price, yield, total return and ability to meet their investment objectives. A description of principal risks is included in each prospectus under the heading “Principal Investment Risks”.

NOTE 10 – GUARANTEES AND INDEMNIFICATIONS

In the normal course of business, the Trust, on behalf of the Funds, enters into contracts with third-party service providers that contain a variety of representations and warranties and that provide general indemnifications. Additionally, under the Trust organizational documents, the officers and Trustees are indemnified against certain liabilities arising out of the performance of their duties to the Trust. The Funds’ maximum exposure under these arrangements is unknown, as it involves possible future claims that may or may not be made against the Funds. The Adviser is of the view that the risk of loss to the Funds in connection with the Funds’ indemnification obligations is remote; however, there can be no assurance that such obligations will not result in material liabilities that adversely affect the Funds.

Note 11 – SUBSEQUENT EVENTS

In preparing these financial statements, management of the Funds has evaluated events and transactions for potential recognition or disclosure through the date the financial statements were issued. There were no transactions that occurred during the period subsequent to August 31, 2023, that materially impacted the amounts or disclosures in the Fund’s financial statements.

 

24

Shareholder Expense Examples

Tema ETF Trust

For the Period Ended August 31, 2023 (Unaudited)

As a shareholder of a Fund in the Tema ETF Trust you incur two types of costs: (1) transaction costs, including brokerage commissions on purchases and sales of Fund shares, and (2) ongoing costs, including management fees and other Fund expenses. This Example is intended to help you understand your ongoing costs (in dollars) (excluding transaction costs) of investing in each Fund and to compare these costs with the ongoing costs of investing in other funds. The example is based on an investment of $1,000 invested at the beginning of each period and held for the entire period through August 31, 2023.

Actual Expenses

The first line of the table below provides information about actual account values based on actual returns and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then, multiply the result by the number in the first line under the heading entitled “Expenses Paid During the Period’’ to estimate the expenses you paid on your account during this period.

Hypothetical Example For Comparison Purposes

The second line of the table provides information about hypothetical account values based on a hypothetical return and hypothetical expenses based on each Fund’s actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Fund’s’ actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in each of the Fund’s and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of the other funds. Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs, such as brokerage commissions paid on purchases and sales of each Fund’s shares. Therefore, the second line of the table is useful in comparing ongoing costs only and will not help you determine the relative total costs of owning different funds. If these transactional costs were included, your costs would have been higher.

Tema American Reshoring ETF1

Annualized
Expense
Ratio

Beginning
Account Value
Inception
1,2,3

Ending
Account Value
(August 31, 2023)

Expenses Paid
During Period (Inception
1,2,3 to
August 31, 2023)

Actual

0.75%

$1,000.00

$1,170.40

$2.51

Hypothetical (5% annual return before expenses)

0.75%

$1,000.00

$1,021.37

$3.81

 

Tema Monopolies and Oligopolies ETF1

Actual

0.75%

$1,000.00

$1,048.00

$2.37

Hypothetical (5% annual return before expenses)

0.75%

$1,000.00

$1,021.37

$3.81

 

Tema Luxury ETF1

Actual

0.75%

$1,000.00

$948.70

$2.26

Hypothetical (5% annual return before expenses)

0.75%

$1,000.00

$1,021.37

$3.81

 

Tema Oncology ETF2

Actual

0.75%

$1,000.00

$997.30

$0.35

Hypothetical (5% annual return before expenses)

0.75%

$1,000.00

$1,021.37

$3.81

 

Tema Global Royalties ETF3

Actual

0.75%

$1,000.00

$1,028.50

$0.31

Hypothetical (5% annual return before expenses)

0.75%

$1,000.00

$1,021.37

$3.81

1The inception date for the Tema American Reshoring ETF, Tema Monopolies and Oligopolies ETF, and Tema Luxury ETF was May 11, 2023. Actual expenses paid during the period are equal to the annualized net expense ratio, multiplied by the average account value over the period, multiplied by 113/366 (to reflect the period).

2The inception date for the Tema Oncology ETF was August 15, 2023. Actual expenses paid during the period are equal to the annualized net expense ratio, multiplied by the average account value over the period, multiplied by 17/366 (to reflect the period).

3The inception date for the Tema Global Royalties ETF was August 17, 2023. Actual expenses paid during the period are equal to the annualized net expense ratio, multiplied by the average account value, multiplied by 15/366 (to reflect the period).

 

25

Board Approval of Investment Advisory Agreement

Tema ETF Trust

APPROVAL OF ADVISORY AGREEMENT AND BOARD CONSIDERATIONS

The Board, including the Independent Trustees, reviewed: (i) the nature and quality of the advisory services to be provided by the Tema Global Limited (the “Adviser”), including the experience and qualifications of the personnel providing such services; (ii) the performance history of Tema Luxury ETF, Tema Monopolies and Oligopolies ETF, and Tema American Reshoring ETF (each a “Fund” and collectively the “Funds), noting that none of the Funds had not yet launched; (iii) the proposed fees and expenses of the Funds, including the proposed advisory fee to be paid by the Funds to the Adviser; (iv) the anticipated profitability of the Funds to the Adviser; (v) potential economies of scale; (vi) possible fall-out benefits to the Adviser and its affiliates (i.e., the ancillary benefits realized by the Adviser and its affiliates from the Adviser’s relationship with the Trust); and (vii) possible conflicts of interest. In considering the approval of the Investment Advisory Agreement, the Board reviewed and analyzed various factors that they determined were relevant, including the factors enumerated below.

The Board exercised its own business judgment in determining its conclusions and its conclusions were based on an evaluation of all of the information provided and were not the result of any one factor. Moreover, each Trustee may have afforded different weight to the various factors in reaching his or her conclusions with respect to the Advisory Agreement.

Nature, Extent and Quality of Services

The Board reviewed materials provided by the Adviser related to the proposed approval of the Investment Advisory Agreement, including a description of its oversight of NEOS Investment Management, LLC (the “Sub-Adviser”), a review of the professional personnel who will be performing services for the Trust, the Adviser’s compliance and risk management infrastructure, its financial strength and resources, and how it will monitor the Sub-Adviser’s performance of trading, portfolio management and operational services to the Funds. The Board also noted the extensive responsibilities that the Adviser will have as investment adviser to the Funds, including: adherence to the Fund’s investment strategy and restrictions, monitoring of the Sub-Adviser’s buying and selling of securities and other transactions, reviewing the Funds’ performance, reviewing the proxies voted by the Adviser and oversight of the creation of custom creation or redemption baskets for authorized participants; oversight of the daily valuation of the Funds’ portfolio holdings; oversight of general Fund compliance with federal and state laws; and implementation of Board directives as they relate to the Funds. The Board also considered research support available to, and management capabilities of, the Funds’ management personnel and that the Adviser will provide oversight of day-to-day Fund operations, including fund accounting, tax matters, administration, compliance and legal assistance in meeting disclosure and regulatory requirements. The Board discussed the extent of the Adviser’s research capabilities, the quality of its compliance infrastructure and the experience of its fund management personnel.

Additionally, the Board received satisfactory responses from the representatives of the Adviser with respect to a series of questions, including: whether the Adviser was involved in any lawsuits or pending regulatory actions; whether the management of other accounts would conflict with its management of the Trust; and whether there are procedures in place to adequately allocate trades among its respective clients.

The Board reviewed the description provided on the practices for monitoring compliance with the Trust’s investment limitations, noting that the Adviser’s CCO would periodically review the portfolio managers’ performance of their duties to ensure compliance under the Adviser’s compliance program. The Board concluded that the Adviser had sufficient quality and depth of personnel, resources, investment methods and compliance policies and procedures essential to performing its duties under the Advisory Agreement and that the nature, overall quality and extent of the management services to be provided by the Adviser to the Trust would be satisfactory.

Performance

Because the Funds had not yet commenced operations, the Trustees could not consider past performance.

Fees and Expenses

As to the costs of the services to be provided by the Adviser, the Board discussed the comparison of advisory fees and total operating expense data and reviewed the Fund’s advisory fee, which is a unitary fee, and overall expenses compared to a peer group comprised of funds in the category constructed by the Adviser and the Sub-Adviser for each Fund, each of which had similar investment objectives and strategies to the relevant Fund. The Board was aware that under the unitary fee arrangement, the Adviser is contractually obligated to pay the fees of each of the Funds’ service providers, with the exception of the Adviser’s advisory fee, and certain other expenses. The Board considered the fact that the Adviser would charge the Fund an investment advisory fee of 99 basis points, subject to the Expense

 

26

Board Approval of Investment Advisory Agreement (Continued)

Tema ETF Trust

 

Limitation Agreement. The Board noted that the advisory fee for the Funds was in some cases greater than the highest ETF in the peer group, noting, however, that the peer ETFs included index or passive ETFs while the Fund will be actively managed. The Board concluded that based on the nature, quality and extent of the Adviser’s services to be provided to the Trust and comparative fee and expense data, the advisory fee charged by the Adviser and the estimated expenses for the Trust in respect of the Funds were reasonable.

Profitability

The Board considered the level of profits that could be expected to accrue to the Adviser with respect to the Trust based on profitability projections and analyses reviewed by the Board and the selected financial information of the Adviser provided by the Adviser to the Board. After review and discussion, the Board concluded the investment advisory relationship would initially be unprofitable to the Adviser and, once the Trust had sufficient assets, the anticipated profit from the Adviser’s relationship with the Trust would not be excessive.

Economies of Scale

As to the extent to which the Trust will realize economies of scale as it grows, and whether the fee levels reflect these economies of scale for the benefit of investors, the Board discussed the Adviser’s expectations for growth of the Trust. The Board determined that because the Funds had not yet commenced operations, economies of scale were not a factor. The Board further determined, however, that to the extent that material economies of scale were to be achieved in the future, and such economies of scale had not been shared with the Funds, the Board would seek to have those economies of scale shared with the Fund in connection with future renewals of the Investment Advisory Agreement. The Board recognized the uncertainty in launching a new investment product and estimating future asset levels.

Fall-Out Benefits

The Board considered potential benefits to the Adviser from acting as investment adviser based on the potential success of the Funds, but that such benefits are not presently quantifiable. The Board noted that the Trust’s service providers are not affiliated with the Adviser, so that such services do not give rise to “fall-out” benefits for the Adviser and its affiliates.

APPROVAL OF SUB-ADVISORY AGREEMENT AND BOARD CONSIDERATIONS

During the Meeting, the Board reviewed and discussed the written materials that were provided by The Board, including the Independent Trustees, reviewed: (i) the nature and quality of the advisory services to be provided by NEOS Investment Management, LLC (the “Sub-Adviser”), including the experience and qualifications of the personnel providing such services; (ii) the performance history of Tema Luxury ETF, Tema Monopolies and Oligopolies ETF, and Tema American Reshoring ETF (each a “Fund” and collectively the “Funds), noting that none of the Funds had not yet launched; (iii) the proposed fees and expense of the Funds, including the proposed sub-advisory fee to be paid by the Adviser to the Sub-Adviser; (iv) the anticipated profitability of the Funds to the Sub-Adviser; (v) potential economies of scale; (vi) possible fall-out benefits to the Sub-Adviser and its affiliates (i.e., the ancillary benefits realized by the Adviser and its affiliates from the Sub-Adviser’s relationship with the Trust); and (vii) possible conflicts of interest. In considering the approval of the Sub-Advisory Agreement, the Board reviewed and analyzed various factors that they determined were relevant, including the factors enumerated below.

Nature, Extent and Quality of Services

As to the nature, quality and extent of the services to be provided by the Sub-Adviser, the Board noted the experience of the portfolio management and personnel of the Sub-Adviser, including their experience in the investment field, education and industry credentials. The Board reviewed the presentation materials prepared by the Sub-Adviser describing its investment process. The Board received satisfactory responses from the Sub-Adviser with respect to a series of questions, including: whether the Sub-Adviser is involved in any lawsuits or pending regulatory actions. The Board discussed the Sub-Adviser’s compliance structure and broker-dealer selection process noting that the Funds would be actively managed equity funds. In consideration of the compliance policies and procedures for the Sub-Adviser included in the meeting materials, the Board concluded that the Sub-Adviser had sufficient quality and depth of personnel, resources, investment methods and compliance policies and procedures essential to performing their duties under the Sub-Advisory Agreement and that the nature, overall quality and extent of investment management services to be provided to the Trust would be satisfactory.

 

27

Board Approval of Investment Advisory Agreement (Continued)

Tema ETF Trust

Performance

As the Funds had not yet commenced operations, the Board was not able to consider past performance.

Fees and Expenses

As to the costs of the services to be provided by the Sub-Adviser, the Board discussed the sub-advisory fee payable by the Adviser to Sub-Adviser, pursuant to the Sub-Advisory Agreement. The Board considered that Sub-Adviser is to be paid by the Adviser and not by the Trust. The Adviser confirmed to the Board that the Adviser was of the opinion that the sub-advisory fees to be paid to the Sub-Adviser were reasonable in light of the anticipated quality of the services to be performed by the Sub-Adviser and the proposed division of services between the Adviser and Sub-Adviser. The Trustees discussed the total fees expected to be paid to the Sub-Adviser, and noted that the Sub-Adviser will receive no other compensation from the Trust or the Adviser, except the sub-advisory fee earned pursuant to the Sub-Advisory Agreement and payable by the Adviser. Based on the representations of the Adviser and Sub-Adviser and the meeting materials provided, the Board concluded that the sub-advisory fee to be paid to the Sub-Adviser was reasonable.

Profitability

As to profits to be realized by the Sub-Adviser, the Trustees noted that all sub-advisory fees will be paid by the Adviser, and not directly paid by the Trust. Consequently, the Board did not consider the costs of services provided by the Sub-Adviser or its profitability to be significant factors.

Economies of Scale

The Board determined that because the Funds had not yet commenced operations, economies of scale were not a factor. The Board further determined, however, that to the extent that material economies of scale were to be achieved in the future, and such economies of scale had not been shared with the Funds, the Board would seek to have those economies of scale shared with the Funds in connection with future renewals of the Sub-Advisor Agreement.

Fall-Out Benefits

The Board considered potential benefits to the Sub-Adviser from acting as sub-adviser to the Funds based on the potential success of the Funds, but that such benefits are not presently quantifiable. The Board noted that the Trust’s service providers are not affiliated with the Sub-Adviser, so that such services do not give rise to “fall-out” benefits for the Sub-Adviser and its affiliates.

 

28

Additional Information (Unaudited)

Tema ETF Trust

 

FREQUENCY DISTRIBUTION OF PREMIUMS AND DISCOUNTS

Information regarding how often shares of the Funds traded on the Exchanges at a price above (i.e., at a premium) or below (i.e., at a discount) the NAV of the Funds are available on the Funds’ website at www.temaetfs.com.

HOUSEHOLDING

Householding is an option available to certain fund investors. Householding is a method of delivery, based on the preference of the individual investor, in which a single copy of certain shareholder documents can be delivered to investors who share the same address, even if their accounts are registered under different names. Please contact your broker-dealer if you are interested in enrolling in householding and receiving a single copy of the prospectuses and other shareholder documents, or if you are currently enrolled in householding and wish to change your householding status.

DISCLOSURE OF PORTFOLIO HOLDINGS

The Funds file their complete schedules of portfolio holdings with the Securities and Exchange Commission (“SEC”) for the first and third quarters of each fiscal year to date as exhibits to their reports on Form N-PORT. The Funds’ Form N-PORT reports are available on the SEC’s website at www.sec.gov. They may also be reviewed and copied at the SEC’s Public Reference Room in Washington, D.C. Information about the Public Reference Room may be obtained by calling 1-800-SEC-0330. In addition, the Funds’ full portfolio holdings are updated daily and available on the Funds’ website at www.temaetfs.com.

PROXY VOTING POLICIES AND PROCEDURES

A description of the policies and procedures the Funds uses to determine how to vote proxies relating to portfolio securities is provided in the Statements of Additional Information (“SAIs”). The SAI is available without charge upon request by calling toll-free at (833) 833-1311, by accessing the SEC’s website at http://www.sec.gov, or by accessing the Funds’ website at www.temaetfs.com. Information on how the Funds’ voted proxies relating to portfolio securities during the most recent 12-month period ended June 30 are available without charge, upon request, by calling (833) 833-1311 or by accessing the website of the SEC.

TRUSTEES AND OFFICERS

Information regarding the Trustees and Officer is provided in the SAI. The SAI is available without charge upon request by calling toll-free at (833) 833-1311, by accessing the SEC’s website at http://www.sec.gov, or by accessing the Fund’s website at www.temaetfs.com.

Fund

Symbol

CUSIP

Tema American Reshoring ETF

RSHO

87975E602

Tema Monopolies and Oligopolies ETF

TOLL

87975E107

Tema Luxury ETF

LUX

87975E305

Tema Oncology ETF

CANC

87975E701

Tema Global Royalties ETF

ROYA

87975E404

This report is intended for the shareholders of the Funds and may not be used as sales literature unless preceded or accompanied by a current prospectus.

Adviser
Tema Global Limited
Brookfield Place
200 Vesey Street, Suite 24106
New York, New York 10281

Distributor
Foreside Fund Services, LLC
Three Canal Plaza, Suite 100
Portland, ME 04101

Administrator, Fund Accountant
& Transfer Agent

U.S. Bancorp Fund Services, LLC
615 East Michigan Street
Milwaukee, WI 53202

 

Custodian
U.S. Bank, N.A. Custody Operations
1555 N. River Center Drive, Suite 302
Milwaukee, WI 53212

Independent Registered
Public Accounting Firm

Cohen & Company, Ltd.
1835 Market Street, Suite 310
Philadelphia, PA 19103

Legal Counsel
Thompson Hine LLP
1919 M Street, N.W., Suite 700
Washington, D.C. 20036-3537

TEMASAR082023